For its fourth fiscal quarter (ending December 31), ADMA Biologics Inc (NASDAQ: ADMA) has reported E.P.S. of $-0.08 compared to $-0.06 a year ago. This performance was $-0.09 short of the consensus estimate of $0.01. E.P.S. were $-0.13 for the latest four quarters through December 31 versus $-0.33 for the same period a year ago.
Recent Price Action
ADMA Biologics Inc (NASDAQ: ADMA) stock declined by -2.5% on 2/28/24. The shares closed at $5.38. Moreover, this decline was accompanied by above average trading volume at 135% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 4.5% during the last week.
Current PriceTarget Research Rating
ADMA is expected to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
ADMA Biologics has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. ADMA Biologics has a poor Appreciation Score of 17 but a very high Power Rating of 87, with the Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment